Production and delivery challenges set up turbulent Year of the Vaccine |
As 2020 closes, regulatory approval of COVID-19 vaccines has raised hopes the world can defeat the pandemic next year. But production and delivery challenges suggest beating the disease will be a marathon whose finish line is still far away.
Europe on Monday followed Britain and the United States in giving a green light to a COVID-19 vaccine from Pfizer (NYSE:PFE) and its partner BioNTech which, like a similar shot from Moderna (NASDAQ:MRNA) that has U.S. emergency approval, demonstrated 95% efficacy in large trials. |
|
|
|
Most Popular Analysis |
|
|
|
|
|
Show More Analysis » |
Weekly Comic |
Wall Street's Blockbuster Year Comes To A Close. Merry Christmas and Happy Holidays From Investing.com! |
|
Show More Comics » |
|
沒有留言:
張貼留言